Table 2. Low-dose oral T3 treatment did not adversely affect heart rate and improved contractility.

	Sham	MI	MI+T3
Heart rate (bpm)	331±14	324±11	334±8
Rate-pressure product (mmHg/min)	39420±2217	35157±1552	36026±1545
LV dP/dt(max) (mmHg/sec)	8324±478	6892±228*	7737±285#
LV dP/dt(min) (mmHg/sec)	8284±656	5119±384***	4967±417***
LVESP (mmHg)	117±2	102±5*	99±5*
LVEDP (mmHg)	6±0.5	10.6±1.6**	11.9±0.8**
Tau (msec)	9.2±0.5	13.3±1.3*	13.4±1.2*
Arterial BP (mmHg)	100±2	93±3	96±3

LV–Left ventricular; dP/dt(max)–maximal rate of LV pressure development

dP/dt(min)–maximal rate of LV pressure decline

ESP–End-systolic pressure

EDP–End-diastolic pressure

BP–Blood pressure

T3–triiodo-L-thyronine

MI–Myocardial Infarction

n = 7–8 sham; 7–9 MI-Veh; 11 MI+T3

*p<0.05

**p<0.01

***p<0.001 vs. Sham

^#p<0.05 vs. MI.